Announcements Trials
Browse Landscape

Phase

Phase 2 1Phase 1 1

Status

Terminated 3Completed 3Active not recruiting 3Recruiting 2

Sponsor Class

OTHER 2

Study Type

Interventional 2

Sponsor

Cancer Type

Gastrointestinal 1Dermatologic 1

Conditions

Neoplasms by Site 1Neoplasms by Histologic Type 1Neoplasms 1Melanoma 1Colonic Neoplasms 1

Interventions

pembrolizumab 551Specimen Handling 465Carboplatin 441Magnetic Resonance Spectroscopy 430Cyclophosphamide 412Cisplatin 397Radiotherapy 313Gemcitabine 309Bevacizumab 307Paclitaxel 294Biopsy 261Drug Therapy 249Capecitabine 242Oxaliplatin 239fludarabine 237Nivolumab 224venetoclax 219Injections 213Docetaxel 205Fluorouracil 203Dexamethasone 187Radiosurgery 172Rituximab 158Pemetrexed 153Standard of Care 146durvalumab 143Leucovorin 139atezolizumab 138toripalimab 134tislelizumab 134

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Recruiting × Interventional × HuMax-IL8 × Clear all
NCT03026140 2026-03-05

NICHE

The Netherlands Cancer Institute

Phase 2 Recruiting
353 enrolled
Gastrointestinal

Colonic Neoplasms

NCT04572451 2025-08-01

Safety of SBRT With Anti-PD1 and Anti-IL-8 for the Treatment of Multiple Metastases in Advanced Solid Tumors and Melanoma

University of Pittsburgh

Phase 1 Recruiting
50 enrolled
Dermatologic

Melanoma, Neoplasms, Neoplasms by Histologic Type, Neoplasms by Site

Data powered by HemOnc (CC BY 4.0) Colophon âš¡